Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 68 entries
Sorted by: Best Match Show Resources per page
Effects of Block Length and Membrane Processing Conditions on the Morphology and Properties of Perfluorosulfonated Poly(arylene ether sulfone) Multiblock Copolymer Membranes for PEMFC.

ACS applied materials & interfaces

Assumma L, Nguyen HD, Iojoiu C, Lyonnard S, Mercier R, Espuche E.
PMID: 26036143
ACS Appl Mater Interfaces. 2015 Jul 01;7(25):13808-20. doi: 10.1021/acsami.5b01835. Epub 2015 Jun 19.

Perfluorosulfonated poly(arylene ether sulfone) multiblock copolymers have been shown to be promising as proton exchange membranes. The commonly used approach for preparation of the membrane is solvent casting; the properties of the resulting membranes are very dependent on the...

Cite
Assumma L, Nguyen HD, Iojoiu C, et al. Effects of Block Length and Membrane Processing Conditions on the Morphology and Properties of Perfluorosulfonated Poly(arylene ether sulfone) Multiblock Copolymer Membranes for PEMFC. ACS Appl Mater Interfaces. 2015;7(25):13808-20doi: 10.1021/acsami.5b01835.
Assumma, L., Nguyen, H. D., Iojoiu, C., Lyonnard, S., Mercier, R., & Espuche, E. (2015). Effects of Block Length and Membrane Processing Conditions on the Morphology and Properties of Perfluorosulfonated Poly(arylene ether sulfone) Multiblock Copolymer Membranes for PEMFC. ACS applied materials & interfaces, 7(25), 13808-20. https://doi.org/10.1021/acsami.5b01835
Assumma, Luca, et al. "Effects of Block Length and Membrane Processing Conditions on the Morphology and Properties of Perfluorosulfonated Poly(arylene ether sulfone) Multiblock Copolymer Membranes for PEMFC." ACS applied materials & interfaces vol. 7,25 (2015): 13808-20. doi: https://doi.org/10.1021/acsami.5b01835
Assumma L, Nguyen HD, Iojoiu C, Lyonnard S, Mercier R, Espuche E. Effects of Block Length and Membrane Processing Conditions on the Morphology and Properties of Perfluorosulfonated Poly(arylene ether sulfone) Multiblock Copolymer Membranes for PEMFC. ACS Appl Mater Interfaces. 2015 Jul 01;7(25):13808-20. doi: 10.1021/acsami.5b01835. Epub 2015 Jun 19. PMID: 26036143.
Copy Download .nbib Format: NLM
Correction: Genetically enhanced T lymphocytes and the intensive care unit.

Oncotarget

Tat T, Li H, Constantinescu CS, Onaciu A, Chira S, Osan C, Pasca S, Petrushev B, Moisoiu V, Micu WT, Berce C, Tranca S, Dima D, Berindan-Neagoe I, Shen J, Tomuleasa C, Qian L.
PMID: 30174800
Oncotarget. 2018 Aug 10;9(62):32097. doi: 10.18632/oncotarget.25983. eCollection 2018 Aug 10.

[This corrects the article DOI: 10.18632/oncotarget.24637.].

Cite
Tat T, Li H, Constantinescu CS, et al. Correction: Genetically enhanced T lymphocytes and the intensive care unit. Oncotarget. 2018;9(62):32097doi: 10.18632/oncotarget.25983.
Tat, T., Li, H., Constantinescu, C. S., Onaciu, A., Chira, S., Osan, C., Pasca, S., Petrushev, B., Moisoiu, V., Micu, W. T., Berce, C., Tranca, S., Dima, D., Berindan-Neagoe, I., Shen, J., Tomuleasa, C., & Qian, L. (2018). Correction: Genetically enhanced T lymphocytes and the intensive care unit. Oncotarget, 9(62), 32097. https://doi.org/10.18632/oncotarget.25983
Tat, Tiberiu, et al. "Correction: Genetically enhanced T lymphocytes and the intensive care unit." Oncotarget vol. 9,62 (2018): 32097. doi: https://doi.org/10.18632/oncotarget.25983
Tat T, Li H, Constantinescu CS, Onaciu A, Chira S, Osan C, Pasca S, Petrushev B, Moisoiu V, Micu WT, Berce C, Tranca S, Dima D, Berindan-Neagoe I, Shen J, Tomuleasa C, Qian L. Correction: Genetically enhanced T lymphocytes and the intensive care unit. Oncotarget. 2018 Aug 10;9(62):32097. doi: 10.18632/oncotarget.25983. eCollection 2018 Aug 10. PMID: 30174800; PMCID: PMC6112836.
Copy Download .nbib Format: NLM
Glioblastoma Multiforme Recurrence: An Exploratory Study of (18)F FPPRGD2 PET/CT.

Radiology

Iagaru A, Mosci C, Mittra E, Zaharchuk G, Fischbein N, Harsh G, Li G, Nagpal S, Recht L, Gambhir SS.
PMID: 27322985
Radiology. 2016 Jul;280(1):328. doi: 10.1148/radiol.2016164020.

No abstract available.

Cite
Iagaru A, Mosci C, Mittra E, et al. Glioblastoma Multiforme Recurrence: An Exploratory Study of (18)F FPPRGD2 PET/CT. Radiology. 2016;280(1):328doi: 10.1148/radiol.2016164020.
Iagaru, A., Mosci, C., Mittra, E., Zaharchuk, G., Fischbein, N., Harsh, G., Li, G., Nagpal, S., Recht, L., & Gambhir, S. S. (2016). Glioblastoma Multiforme Recurrence: An Exploratory Study of (18)F FPPRGD2 PET/CT. Radiology, 280(1), 328. https://doi.org/10.1148/radiol.2016164020
Iagaru, Andrei, et al. "Glioblastoma Multiforme Recurrence: An Exploratory Study of (18)F FPPRGD2 PET/CT." Radiology vol. 280,1 (2016): 328. doi: https://doi.org/10.1148/radiol.2016164020
Iagaru A, Mosci C, Mittra E, Zaharchuk G, Fischbein N, Harsh G, Li G, Nagpal S, Recht L, Gambhir SS. Glioblastoma Multiforme Recurrence: An Exploratory Study of (18)F FPPRGD2 PET/CT. Radiology. 2016 Jul;280(1):328. doi: 10.1148/radiol.2016164020. PMID: 27322985.
Copy Download .nbib Format: NLM
Baclofen for the Treatment of Alcohol Use Disorder in Patients With Liver Cirrhosis: 10 Years After the First Evidence.

Frontiers in psychiatry

Mosoni C, Dionisi T, Vassallo GA, Mirijello A, Tarli C, Antonelli M, Sestito L, Rando MM, Tosoni A, De Cosmo S, Gasbarrini A, Addolorato G.
PMID: 30327620
Front Psychiatry. 2018 Oct 01;9:474. doi: 10.3389/fpsyt.2018.00474. eCollection 2018.

Alcohol Use Disorder (AUD) is a chronic and relapsing condition characterized by harmful alcohol intake and behavioral-cognitive changes. AUD is the most common cause of liver disease in the Western world. Alcohol abstinence is the cornerstone of therapy in...

Cite
Mosoni C, Dionisi T, Vassallo GA, et al. Baclofen for the Treatment of Alcohol Use Disorder in Patients With Liver Cirrhosis: 10 Years After the First Evidence. Front Psychiatry. 2018;9:474doi: 10.3389/fpsyt.2018.00474.
Mosoni, C., Dionisi, T., Vassallo, G. A., Mirijello, A., Tarli, C., Antonelli, M., Sestito, L., Rando, M. M., Tosoni, A., De Cosmo, S., Gasbarrini, A., & Addolorato, G. (2018). Baclofen for the Treatment of Alcohol Use Disorder in Patients With Liver Cirrhosis: 10 Years After the First Evidence. Frontiers in psychiatry, 9474. https://doi.org/10.3389/fpsyt.2018.00474
Mosoni, Carolina, et al. "Baclofen for the Treatment of Alcohol Use Disorder in Patients With Liver Cirrhosis: 10 Years After the First Evidence." Frontiers in psychiatry vol. 9 (2018): 474. doi: https://doi.org/10.3389/fpsyt.2018.00474
Mosoni C, Dionisi T, Vassallo GA, Mirijello A, Tarli C, Antonelli M, Sestito L, Rando MM, Tosoni A, De Cosmo S, Gasbarrini A, Addolorato G. Baclofen for the Treatment of Alcohol Use Disorder in Patients With Liver Cirrhosis: 10 Years After the First Evidence. Front Psychiatry. 2018 Oct 01;9:474. doi: 10.3389/fpsyt.2018.00474. eCollection 2018. PMID: 30327620; PMCID: PMC6174362.
Copy Download .nbib Format: NLM
Characterization of Carbon Nanomaterials Dispersions: Can Metal Decoration of MWCNTs Improve Their Physicochemical Properties?.

Nanomaterials (Basel, Switzerland)

Brandão ATSC, Rosoiu S, Costa R, Silva AF, Anicai L, Enachescu M, Pereira CM.
PMID: 35010051
Nanomaterials (Basel). 2021 Dec 29;12(1). doi: 10.3390/nano12010099.

A suitable dispersion of carbon materials (e.g., carbon nanotubes (CNTs)) in an appropriate dispersant media, is a prerequisite for many technological applications (e.g., additive purposes, functionalization, mechanical reinforced materials for electrolytes and electrodes for energy storage applications, etc.). Deep...

Cite
Brandão ATSC, Rosoiu S, Costa R, et al. Characterization of Carbon Nanomaterials Dispersions: Can Metal Decoration of MWCNTs Improve Their Physicochemical Properties?. Nanomaterials (Basel). 2021;12(1)doi: 10.3390/nano12010099.
Brandão, A. T. S. C., Rosoiu, S., Costa, R., Silva, A. F., Anicai, L., Enachescu, M., & Pereira, C. M. (2021). Characterization of Carbon Nanomaterials Dispersions: Can Metal Decoration of MWCNTs Improve Their Physicochemical Properties?. Nanomaterials (Basel, Switzerland), 12(1), . https://doi.org/10.3390/nano12010099
Brandão, Ana T S C, et al. "Characterization of Carbon Nanomaterials Dispersions: Can Metal Decoration of MWCNTs Improve Their Physicochemical Properties?." Nanomaterials (Basel, Switzerland) vol. 12,1 (2021). doi: https://doi.org/10.3390/nano12010099
Brandão ATSC, Rosoiu S, Costa R, Silva AF, Anicai L, Enachescu M, Pereira CM. Characterization of Carbon Nanomaterials Dispersions: Can Metal Decoration of MWCNTs Improve Their Physicochemical Properties?. Nanomaterials (Basel). 2021 Dec 29;12(1). doi: 10.3390/nano12010099. PMID: 35010051.
Copy Download .nbib Format: NLM
Characterization of Carbon Nanomaterials Dispersions: Can Metal Decoration of MWCNTs Improve Their Physicochemical Properties?.

Nanomaterials (Basel, Switzerland)

Brandão ATSC, Rosoiu S, Costa R, Silva AF, Anicai L, Enachescu M, Pereira CM.
PMID: 35010051
Nanomaterials (Basel). 2021 Dec 29;12(1). doi: 10.3390/nano12010099.

A suitable dispersion of carbon materials (e.g., carbon nanotubes (CNTs)) in an appropriate dispersant media, is a prerequisite for many technological applications (e.g., additive purposes, functionalization, mechanical reinforced materials for electrolytes and electrodes for energy storage applications, etc.). Deep...

Cite
Brandão ATSC, Rosoiu S, Costa R, et al. Characterization of Carbon Nanomaterials Dispersions: Can Metal Decoration of MWCNTs Improve Their Physicochemical Properties?. Nanomaterials (Basel). 2021;12(1)doi: 10.3390/nano12010099.
Brandão, A. T. S. C., Rosoiu, S., Costa, R., Silva, A. F., Anicai, L., Enachescu, M., & Pereira, C. M. (2021). Characterization of Carbon Nanomaterials Dispersions: Can Metal Decoration of MWCNTs Improve Their Physicochemical Properties?. Nanomaterials (Basel, Switzerland), 12(1), . https://doi.org/10.3390/nano12010099
Brandão, Ana T S C, et al. "Characterization of Carbon Nanomaterials Dispersions: Can Metal Decoration of MWCNTs Improve Their Physicochemical Properties?." Nanomaterials (Basel, Switzerland) vol. 12,1 (2021). doi: https://doi.org/10.3390/nano12010099
Brandão ATSC, Rosoiu S, Costa R, Silva AF, Anicai L, Enachescu M, Pereira CM. Characterization of Carbon Nanomaterials Dispersions: Can Metal Decoration of MWCNTs Improve Their Physicochemical Properties?. Nanomaterials (Basel). 2021 Dec 29;12(1). doi: 10.3390/nano12010099. PMID: 35010051; PMCID: PMC8746781.
Copy Download .nbib Format: NLM
Initial evaluation of (4S)-4-(3-[.

EJNMMI research

Park SY, Mosci C, Kumar M, Wardak M, Koglin N, Bullich S, Mueller A, Berndt M, Stephens AW, Chin FT, Gambhir SS, Mittra ES.
PMID: 32857284
EJNMMI Res. 2020 Aug 28;10(1):100. doi: 10.1186/s13550-020-00678-2.

PURPOSE: (4S)-4-(3-[METHODS: A total of 15 subjects with HNC (n = 5), CRC (n = 5), or NHL (n = 5) were recruited (mean age 66.2 years, range 44-87 years). 301.4 ± 28.1 MBq (8.1 ± 0.8 mCi) of...

Cite
Park SY, Mosci C, Kumar M, et al. Initial evaluation of (4S)-4-(3-[. EJNMMI Res. 2020;10(1):100doi: 10.1186/s13550-020-00678-2.
Park, S. Y., Mosci, C., Kumar, M., Wardak, M., Koglin, N., Bullich, S., Mueller, A., Berndt, M., Stephens, A. W., Chin, F. T., Gambhir, S. S., & Mittra, E. S. (2020). Initial evaluation of (4S)-4-(3-[. EJNMMI research, 10(1), 100. https://doi.org/10.1186/s13550-020-00678-2
Park, Sonya Y, et al. "Initial evaluation of (4S)-4-(3-[." EJNMMI research vol. 10,1 (2020): 100. doi: https://doi.org/10.1186/s13550-020-00678-2
Park SY, Mosci C, Kumar M, Wardak M, Koglin N, Bullich S, Mueller A, Berndt M, Stephens AW, Chin FT, Gambhir SS, Mittra ES. Initial evaluation of (4S)-4-(3-[. EJNMMI Res. 2020 Aug 28;10(1):100. doi: 10.1186/s13550-020-00678-2. PMID: 32857284; PMCID: PMC7455665.
Copy Download .nbib Format: NLM
A Novel 3q29 Deletion in Association With Developmental Delay and Heart Malformation-Case Report With Literature Review.

Frontiers in pediatrics

Chirita Emandi A, Dobrescu AI, Doros G, Hyon C, Miclea D, Popoiu C, Puiu M, Arghirescu S.
PMID: 31338352
Front Pediatr. 2019 Jul 08;7:270. doi: 10.3389/fped.2019.00270. eCollection 2019.

3q29 deletion syndrome is a rare disorder, causing a complex phenotype. Clinical features are variable and relatively non-specific. Our report aims to present an atypical,

Cite
Chirita Emandi A, Dobrescu AI, Doros G, et al. A Novel 3q29 Deletion in Association With Developmental Delay and Heart Malformation-Case Report With Literature Review. Front Pediatr. 2019;7:270doi: 10.3389/fped.2019.00270.
Chirita Emandi, A., Dobrescu, A. I., Doros, G., Hyon, C., Miclea, D., Popoiu, C., Puiu, M., & Arghirescu, S. (2019). A Novel 3q29 Deletion in Association With Developmental Delay and Heart Malformation-Case Report With Literature Review. Frontiers in pediatrics, 7270. https://doi.org/10.3389/fped.2019.00270
Chirita Emandi, Adela, et al. "A Novel 3q29 Deletion in Association With Developmental Delay and Heart Malformation-Case Report With Literature Review." Frontiers in pediatrics vol. 7 (2019): 270. doi: https://doi.org/10.3389/fped.2019.00270
Chirita Emandi A, Dobrescu AI, Doros G, Hyon C, Miclea D, Popoiu C, Puiu M, Arghirescu S. A Novel 3q29 Deletion in Association With Developmental Delay and Heart Malformation-Case Report With Literature Review. Front Pediatr. 2019 Jul 08;7:270. doi: 10.3389/fped.2019.00270. eCollection 2019. PMID: 31338352; PMCID: PMC6628938.
Copy Download .nbib Format: NLM
Thyroid Eye Disease: Navigating the New Treatment Landscape.

Journal of the Endocrine Society

Dosiou C, Kossler AL.
PMID: 33948524
J Endocr Soc. 2021 Mar 17;5(5):bvab034. doi: 10.1210/jendso/bvab034. eCollection 2021 May 01.

Thyroid eye disease (TED) is a complex inflammatory disease that can have a long clinical course with sight-threatening and debilitating ocular sequelae. Until recently, there were limited therapeutic options available. In the last decade we have gained a deeper...

Cite
Dosiou C, Kossler AL. Thyroid Eye Disease: Navigating the New Treatment Landscape. J Endocr Soc. 2021;5(5):bvab034doi: 10.1210/jendso/bvab034.
Dosiou, C., & Kossler, A. L. (2021). Thyroid Eye Disease: Navigating the New Treatment Landscape. Journal of the Endocrine Society, 5(5), bvab034. https://doi.org/10.1210/jendso/bvab034
Dosiou, Chrysoula, and Kossler, Andrea Lora. "Thyroid Eye Disease: Navigating the New Treatment Landscape." Journal of the Endocrine Society vol. 5,5 (2021): bvab034. doi: https://doi.org/10.1210/jendso/bvab034
Dosiou C, Kossler AL. Thyroid Eye Disease: Navigating the New Treatment Landscape. J Endocr Soc. 2021 Mar 17;5(5):bvab034. doi: 10.1210/jendso/bvab034. eCollection 2021 May 01. PMID: 33948524; PMCID: PMC8078830.
Copy Download .nbib Format: NLM
Assessing Measurable Residual Disease in Chronic Myeloid Leukemia. BCR-ABL1 IS in the .

Frontiers in oncology

Moisoiu V, Teodorescu P, Parajdi L, Pasca S, Zdrenghea M, Dima D, Precup R, Tomuleasa C, Soverini S.
PMID: 31608223
Front Oncol. 2019 Sep 23;9:863. doi: 10.3389/fonc.2019.00863. eCollection 2019.

Chronic myelogenous leukemia (CML) is a malignancy of the myeloid cell lineage characterized by a recurrent chromosomal abnormality: the Philadelphia chromosome, which results from the reciprocal translocation of the chromosomes 9 and 22. The Philadelphia chromosome contains a fusion...

Cite
Moisoiu V, Teodorescu P, Parajdi L, et al. Assessing Measurable Residual Disease in Chronic Myeloid Leukemia. BCR-ABL1 IS in the . Front Oncol. 2019;9:863doi: 10.3389/fonc.2019.00863.
Moisoiu, V., Teodorescu, P., Parajdi, L., Pasca, S., Zdrenghea, M., Dima, D., Precup, R., Tomuleasa, C., & Soverini, S. (2019). Assessing Measurable Residual Disease in Chronic Myeloid Leukemia. BCR-ABL1 IS in the . Frontiers in oncology, 9863. https://doi.org/10.3389/fonc.2019.00863
Moisoiu, Vlad, et al. "Assessing Measurable Residual Disease in Chronic Myeloid Leukemia. BCR-ABL1 IS in the ." Frontiers in oncology vol. 9 (2019): 863. doi: https://doi.org/10.3389/fonc.2019.00863
Moisoiu V, Teodorescu P, Parajdi L, Pasca S, Zdrenghea M, Dima D, Precup R, Tomuleasa C, Soverini S. Assessing Measurable Residual Disease in Chronic Myeloid Leukemia. BCR-ABL1 IS in the . Front Oncol. 2019 Sep 23;9:863. doi: 10.3389/fonc.2019.00863. eCollection 2019. PMID: 31608223; PMCID: PMC6768007.
Copy Download .nbib Format: NLM
C2'-F Stereoconfiguration As a Puckering Switch for Base Stacking at the Dinucleotide Level.

The Journal of organic chemistry

Moriou C, Da Silva AD, Vianelli Prado MJ, Denhez C, Plashkevych O, Chattopadhyaya J, Guillaume D, Clivio P.
PMID: 29364674
J Org Chem. 2018 Feb 16;83(4):2473-2478. doi: 10.1021/acs.joc.7b03186. Epub 2018 Feb 01.

Fluorine configuration at C2' of the bis(2'-fluorothymidine) dinucleotide is demonstrated to drive intramolecular base stacking. 2'-β F-Configuration drastically reduces stacking compared to the 2'-α series. Hence, base stacking emerges as being tunable by the C2'-F stereoconfiguration through dramatic puckering...

Cite
Moriou C, Da Silva AD, Vianelli Prado MJ, et al. C2'-F Stereoconfiguration As a Puckering Switch for Base Stacking at the Dinucleotide Level. J Org Chem. 2018;83(4):2473-2478doi: 10.1021/acs.joc.7b03186.
Moriou, C., Da Silva, A. D., Vianelli Prado, M. J., Denhez, C., Plashkevych, O., Chattopadhyaya, J., Guillaume, D., & Clivio, P. (2018). C2'-F Stereoconfiguration As a Puckering Switch for Base Stacking at the Dinucleotide Level. The Journal of organic chemistry, 83(4), 2473-2478. https://doi.org/10.1021/acs.joc.7b03186
Moriou, Céline, et al. "C2'-F Stereoconfiguration As a Puckering Switch for Base Stacking at the Dinucleotide Level." The Journal of organic chemistry vol. 83,4 (2018): 2473-2478. doi: https://doi.org/10.1021/acs.joc.7b03186
Moriou C, Da Silva AD, Vianelli Prado MJ, Denhez C, Plashkevych O, Chattopadhyaya J, Guillaume D, Clivio P. C2'-F Stereoconfiguration As a Puckering Switch for Base Stacking at the Dinucleotide Level. J Org Chem. 2018 Feb 16;83(4):2473-2478. doi: 10.1021/acs.joc.7b03186. Epub 2018 Feb 01. PMID: 29364674.
Copy Download .nbib Format: NLM
(18)F NaF PET/CT in the Assessment of Malignant Bone Disease.

PET clinics

Mosci C, Iagaru A.
PMID: 27157457
PET Clin. 2012 Jul;7(3):263-74. doi: 10.1016/j.cpet.2012.04.003. Epub 2012 May 24.

Diagnostic imaging plays a major role in the evaluation of patients with malignant bone disease. (18)F-Labeled sodium fluoride ((18)F NaF) is a positron-emitting radiopharmaceutical with desirable characteristics (rapid blood clearance and bone uptake) for high-quality functional imaging of the...

Cite
Mosci C, Iagaru A. (18)F NaF PET/CT in the Assessment of Malignant Bone Disease. PET Clin. 2012;7(3):263-74doi: 10.1016/j.cpet.2012.04.003.
Mosci, C., & Iagaru, A. (2012). (18)F NaF PET/CT in the Assessment of Malignant Bone Disease. PET clinics, 7(3), 263-74. https://doi.org/10.1016/j.cpet.2012.04.003
Mosci, Camila, and Iagaru, Andrei. "(18)F NaF PET/CT in the Assessment of Malignant Bone Disease." PET clinics vol. 7,3 (2012): 263-74. doi: https://doi.org/10.1016/j.cpet.2012.04.003
Mosci C, Iagaru A. (18)F NaF PET/CT in the Assessment of Malignant Bone Disease. PET Clin. 2012 Jul;7(3):263-74. doi: 10.1016/j.cpet.2012.04.003. Epub 2012 May 24. PMID: 27157457.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 68 entries